Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

250.80
Delayed Data
As of May 26
 -2.17 / -0.86%
Today’s Change
205.42
Today|||52-Week Range
307.33
-3.98%
Year-to-Date
Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer
May 26 / Zacks.com - Paid Partner Content
Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen I...
May 22 / GuruFocus News - Paid Partner Content
Charting the Biotechs
May 26 / TheStreet.com - Paid Partner Content
Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclero...
May 22 / TheStreet.com - Paid Partner Content
Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?
May 26 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer De...
May 17 / Zacks.com - Paid Partner Content
Biogen's Fampyra Conditional Approval Converted to Standard
May 25 / Zacks.com - Paid Partner Content
Biogen (BIIB) Buys Stroke Candidate Cirara for $120M
May 16 / Zacks.com - Paid Partner Content
Jeff Ubben Buys 1, Sells 1 in 1st Quarter
May 24 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close252.97
Today’s open252.59
Day’s range250.51 - 253.62
Volume833,069
Average volume (3 months)1,625,502
Market cap$53.2B
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+1.40%
Earnings growth (next 5 years)+5.50%
Revenue growth (last year)+9.37%
P/E ratio15.7
Price/Sales6.09
Price/Book4.46

Competitors

 Today’s
change
Today’s
% change
ILMNIllumina Inc+2.15+1.24%
GILDGilead Sciences-0.06-0.09%
BIVVBioverativ Inc+1.74+3.16%
TECHBio-Techne Corp+0.20+0.18%
Data as of 3:59pm ET, 05/26/2017

Financials

Next reporting dateJuly 27, 2017
EPS forecast (this quarter)$4.63
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Chief Financial Officer &
Executive Vice President
Paul J. Clancy
Corporate headquarters
Cambridge, Massachusetts

Forecasts